Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Halozyme Therapeutic
(NQ:
HALO
)
40.68
-0.05 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
707,395
Open
40.82
Bid (Size)
39.75 (10)
Ask (Size)
41.30 (20)
Prev. Close
40.73
Today's Range
40.80 - 40.81
52wk Range
29.85 - 45.00
Shares Outstanding
142,334,900
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
March 18, 2024
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.
Via
Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
March 14, 2024
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
Performance
YTD
+8.80%
+8.80%
1 Month
+2.11%
+2.11%
3 Month
+9.50%
+9.50%
6 Month
+3.91%
+3.91%
1 Year
+6.52%
+6.52%
More News
Read More
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
Via
InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
March 11, 2024
Via
Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
March 01, 2024
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
February 21, 2024
Via
Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
February 21, 2024
Via
Benzinga
Halozyme Therapeutics: Q4 Earnings Insights
February 20, 2024
Via
Benzinga
Earnings Preview: Halozyme Therapeutics
February 19, 2024
Via
Benzinga
Earnings Scheduled For February 20, 2024
February 20, 2024
Via
Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
February 19, 2024
Via
Chartmill
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
February 15, 2024
Via
Benzinga
NASDAQ:HALO, an undervalued stock with good fundamentals.
February 09, 2024
Via
Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
January 31, 2024
Via
Chartmill
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
Via
Benzinga
NASDAQ:HALO: good value for what you're paying.
January 19, 2024
Via
Chartmill
Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts
January 18, 2024
Via
Benzinga
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
January 29, 2024
Via
Chartmill
3 Biotech Stocks to Sell in January Before They Crash and Burn
January 25, 2024
Via
InvestorPlace
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Via
Benzinga
Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe
January 16, 2024
Via
Benzinga
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
January 16, 2024
Via
The Motley Fool
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
January 10, 2024
Via
Chartmill
Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced.
January 08, 2024
Via
Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
December 29, 2023
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.